Symbols / CGTX $0.87 +0.08% Cognition Therapeutics, Inc.
CGTX Chart
About
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 77.62M |
| Enterprise Value | 41.39M | Income | -23.49M | Sales | — |
| Book/sh | 0.39 | Cash/sh | 0.41 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -2.90 | PEG | — |
| P/S | — | P/B | 2.26 | P/C | — |
| EV/EBITDA | -0.87 | EV/Sales | — | Quick Ratio | 3.36 |
| Current Ratio | 3.45 | Debt/Eq | 1.86 | LT Debt/Eq | — |
| EPS (ttm) | -0.32 | EPS next Y | -0.30 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 07:00 | ROA | -75.99% |
| ROE | -88.59% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 89.35M |
| Shs Float | 82.53M | Short Float | 8.48% | Short Ratio | 10.77 |
| Short Interest | — | 52W High | 3.83 | 52W Low | 0.22 |
| Beta | 1.40 | Avg Volume | 1.06M | Volume | 77.16K |
| Target Price | $3.50 | Recom | Strong_buy | Prev Close | $0.87 |
| Price | $0.87 | Change | 0.08% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-11-21 | reit | B. Riley Securities | Buy → Buy | $3 |
| 2025-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-05-27 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-05-08 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-21 | main | Chardan Capital | Buy → Buy | $8 |
| 2025-02-26 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-12-19 | up | B. Riley Securities | Neutral → Buy | $2 |
| 2024-12-19 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-12-19 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-15 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-31 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-06 | down | B. Riley Securities | Buy → Neutral | $1 |
- CGTX Stock Price, Quote & Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill hu, 02 Apr 2026 07
- Cognition Therapeutics sets March 26 webcast on 2025 results - stocktitan.net Mon, 23 Mar 2026 07
- COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings - quiverquant.com hu, 26 Mar 2026 11
- Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - finance.yahoo.com Fri, 05 Dec 2025 08
- CGTX Should I Buy - Intellectia AI hu, 02 Apr 2026 15
- Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX) - Seeking Alpha Fri, 21 Nov 2025 08
- $80M NIH-backed Alzheimer’s trial has 545 patients, data due 2027 - stocktitan.net ue, 31 Mar 2026 20
- Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - finance.yahoo.com Mon, 23 Mar 2026 07
- CGTX Technical Analysis & Stock Price Forecast - Intellectia AI hu, 02 Apr 2026 07
- Dementia trial drug slowed neuropsychiatric decline 86% vs placebo - stocktitan.net ue, 17 Mar 2026 07
- Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade - finance.yahoo.com Wed, 08 Oct 2025 07
- No approved DLB psychosis drugs; Cognition maps FDA path for one - stocktitan.net hu, 26 Mar 2026 07
- Cognition Therapeutics (NASDAQ: CGTX) maps Phase 3 AD trial after 95% decline slowdown - stocktitan.net Mon, 01 Dec 2025 08
- Cognition (NASDAQ: CGTX) completes Phase 2 enrollment at 540; 15% on Leqembi or Kisunla - stocktitan.net hu, 13 Nov 2025 08
- DLB psychosis often untreated — zervimesine study targets hallucinations - stocktitan.net Mon, 02 Mar 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
24.39
-29.13%
|
34.42
+32.79%
|
25.92
+21.49%
|
21.33
|
| Research And Development |
|
37.19
-10.77%
|
41.68
+12.04%
|
37.20
+22.66%
|
30.32
|
| Selling General And Administration |
|
10.61
-13.65%
|
12.29
-9.15%
|
13.53
+2.28%
|
13.23
|
| General And Administrative Expense |
|
10.61
-13.65%
|
12.29
-9.15%
|
13.53
+2.28%
|
13.23
|
| Other Gand A |
|
10.61
-13.65%
|
12.29
-9.15%
|
13.53
+2.28%
|
13.23
|
| Other Operating Expenses |
|
-23.41
-19.73%
|
-19.55
+21.19%
|
-24.80
-11.65%
|
-22.22
|
| Total Expenses |
|
24.39
-29.13%
|
34.42
+32.79%
|
25.92
+21.49%
|
21.33
|
| Operating Income |
|
-24.39
+29.13%
|
-34.42
-32.79%
|
-25.92
-21.49%
|
-21.33
|
| Total Operating Income As Reported |
|
-47.80
+11.43%
|
-53.97
-6.39%
|
-50.72
-16.47%
|
-43.55
|
| EBITDA |
|
-23.25
+30.98%
|
-33.68
-32.03%
|
-25.51
-20.70%
|
-21.13
|
| Normalized EBITDA |
|
-23.25
+30.58%
|
-33.48
-31.27%
|
-25.51
-20.70%
|
-21.13
|
| Reconciled Depreciation |
|
0.23
-14.29%
|
0.27
+5.56%
|
0.25
+7.23%
|
0.23
|
| EBIT |
|
-23.47
+30.85%
|
-33.95
-31.77%
|
-25.76
-20.55%
|
-21.37
|
| Total Unusual Items |
|
0.00
+100.00%
|
-0.20
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-0.20
|
0.00
|
0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.20
|
0.00
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Pretax Income |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Net Non Operating Interest Income Expense |
|
-0.01
+48.00%
|
-0.03
+7.41%
|
-0.03
+3.57%
|
-0.03
|
| Interest Expense Non Operating |
|
0.01
-48.00%
|
0.03
-7.41%
|
0.03
-3.57%
|
0.03
|
| Net Interest Income |
|
-0.01
+48.00%
|
-0.03
+7.41%
|
-0.03
+3.57%
|
-0.03
|
| Interest Expense |
|
0.01
-48.00%
|
0.03
-7.41%
|
0.03
-3.57%
|
0.03
|
| Other Income Expense |
|
0.92
+95.12%
|
0.47
+198.10%
|
0.16
+551.43%
|
-0.04
|
| Other Non Operating Income Expenses |
|
0.92
+37.99%
|
0.67
+321.52%
|
0.16
+551.43%
|
-0.04
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Business |
|
0.00
+100.00%
|
-0.20
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Net Income From Continuing Operation Net Minority Interest |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Net Income From Continuing And Discontinued Operation |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Net Income Continuous Operations |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Normalized Income |
|
-23.49
+30.46%
|
-33.78
-30.98%
|
-25.79
-20.52%
|
-21.40
|
| Net Income Common Stockholders |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Diluted EPS |
|
-0.32
+62.79%
|
-0.86
+0.00%
|
-0.86
+5.49%
|
-0.91
|
| Basic EPS |
|
-0.32
+62.79%
|
-0.86
+0.00%
|
-0.86
+5.49%
|
-0.91
|
| Basic Average Shares |
|
72.77
+83.15%
|
39.73
+32.31%
|
30.03
+27.03%
|
23.64
|
| Diluted Average Shares |
|
72.77
+83.15%
|
39.73
+32.31%
|
30.03
+27.03%
|
23.64
|
| Diluted NI Availto Com Stockholders |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
48.39
+60.05%
|
30.23
-14.02%
|
35.16
-30.27%
|
50.42
|
| Current Assets |
|
47.99
+62.38%
|
29.55
-13.64%
|
34.22
-28.18%
|
47.65
|
| Cash Cash Equivalents And Short Term Investments |
|
36.81
+47.19%
|
25.01
-16.42%
|
29.92
-28.01%
|
41.56
|
| Cash And Cash Equivalents |
|
36.81
+47.19%
|
25.01
-16.42%
|
29.92
-28.01%
|
41.56
|
| Receivables |
|
9.92
+269.43%
|
2.69
+109.68%
|
1.28
-65.11%
|
3.67
|
| Other Receivables |
|
9.92
+269.43%
|
2.69
+109.68%
|
1.28
-65.11%
|
3.67
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.19
|
0.00
|
—
|
—
|
| Other Current Assets |
|
1.07
-42.58%
|
1.86
-38.39%
|
3.02
+25.11%
|
2.41
|
| Total Non Current Assets |
|
0.40
-41.24%
|
0.68
-27.84%
|
0.94
-66.13%
|
2.78
|
| Net PPE |
|
0.40
-41.24%
|
0.68
-27.84%
|
0.94
-10.04%
|
1.05
|
| Gross PPE |
|
0.59
-68.07%
|
1.83
-7.79%
|
1.99
-0.45%
|
2.00
|
| Accumulated Depreciation |
|
-0.19
+83.82%
|
-1.16
-10.20%
|
-1.05
-10.07%
|
-0.95
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.31
-38.55%
|
0.50
-24.20%
|
0.66
-19.19%
|
0.81
|
| Machinery Furniture Equipment |
|
0.14
-1.43%
|
0.14
+0.00%
|
0.14
+8.53%
|
0.13
|
| Other Properties |
|
0.14
-88.14%
|
1.20
+0.34%
|
1.19
+12.87%
|
1.06
|
| Other Non Current Assets |
|
—
|
—
|
—
|
1.73
|
| Total Liabilities Net Minority Interest |
|
14.12
+22.94%
|
11.48
+7.44%
|
10.69
+5.04%
|
10.18
|
| Current Liabilities |
|
13.92
+24.97%
|
11.14
+9.57%
|
10.17
+30.46%
|
7.79
|
| Payables And Accrued Expenses |
|
11.54
+42.92%
|
8.08
+22.67%
|
6.58
+48.31%
|
4.44
|
| Payables |
|
1.12
-43.60%
|
1.98
-46.31%
|
3.69
+14.89%
|
3.22
|
| Accounts Payable |
|
1.12
-43.60%
|
1.98
-46.31%
|
3.69
+14.89%
|
3.22
|
| Current Accrued Expenses |
|
10.43
+71.09%
|
6.09
+110.87%
|
2.89
+136.11%
|
1.22
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.57
+2.82%
|
1.53
+30.99%
|
1.17
+33.91%
|
0.87
|
| Current Debt And Capital Lease Obligation |
|
0.44
-6.14%
|
0.47
-34.26%
|
0.72
-8.30%
|
0.78
|
| Current Debt |
|
0.31
+10.04%
|
0.28
-48.71%
|
0.54
-14.20%
|
0.63
|
| Other Current Borrowings |
|
0.31
+10.04%
|
0.28
-48.71%
|
0.54
-14.20%
|
0.63
|
| Current Capital Lease Obligation |
|
0.14
-29.53%
|
0.19
+10.92%
|
0.17
+16.78%
|
0.15
|
| Current Deferred Liabilities |
|
0.37
-65.57%
|
1.07
-37.33%
|
1.70
-0.06%
|
1.70
|
| Current Deferred Revenue |
|
0.37
-65.57%
|
1.07
-37.33%
|
1.70
-0.06%
|
1.70
|
| Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.20
-42.98%
|
0.34
-34.23%
|
0.52
-78.16%
|
2.38
|
| Long Term Debt And Capital Lease Obligation |
|
0.20
-42.98%
|
0.34
-34.23%
|
0.52
-25.18%
|
0.69
|
| Long Term Capital Lease Obligation |
|
0.20
-42.98%
|
0.34
-34.23%
|
0.52
-25.18%
|
0.69
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
1.69
|
| Non Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
1.69
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
34.27
+82.78%
|
18.75
-23.39%
|
24.47
-39.19%
|
40.25
|
| Common Stock Equity |
|
34.27
+82.78%
|
18.75
-23.39%
|
24.47
-39.19%
|
40.25
|
| Capital Stock |
|
0.09
+50.00%
|
0.06
+87.50%
|
0.03
+10.34%
|
0.03
|
| Common Stock |
|
0.09
+50.00%
|
0.06
+87.50%
|
0.03
+10.34%
|
0.03
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
88.90
+48.53%
|
59.85
+86.08%
|
32.17
+10.95%
|
28.99
|
| Ordinary Shares Number |
|
88.90
+48.53%
|
59.85
+86.08%
|
32.17
+10.95%
|
28.99
|
| Additional Paid In Capital |
|
232.83
+20.11%
|
193.85
+16.90%
|
165.83
+6.42%
|
155.82
|
| Retained Earnings |
|
-198.65
-13.41%
|
-175.16
-24.06%
|
-141.19
-22.35%
|
-115.40
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
+100.00%
|
-0.20
+2.01%
|
-0.20
|
| Other Equity Adjustments |
|
—
|
—
|
-0.20
+2.01%
|
-0.20
|
| Total Equity Gross Minority Interest |
|
34.27
+82.78%
|
18.75
-23.39%
|
24.47
-39.19%
|
40.25
|
| Total Capitalization |
|
34.27
+82.78%
|
18.75
-23.39%
|
24.47
-39.19%
|
40.25
|
| Working Capital |
|
34.07
+85.02%
|
18.41
-23.45%
|
24.05
-39.64%
|
39.85
|
| Invested Capital |
|
34.58
+81.71%
|
19.03
-23.94%
|
25.02
-38.81%
|
40.88
|
| Total Debt |
|
0.64
-21.62%
|
0.81
-34.25%
|
1.24
-16.24%
|
1.48
|
| Capital Lease Obligations |
|
0.33
-38.13%
|
0.54
-22.91%
|
0.69
-17.77%
|
0.84
|
| Net Tangible Assets |
|
34.27
+82.78%
|
18.75
-23.39%
|
24.47
-39.19%
|
40.25
|
| Tangible Book Value |
|
34.27
+82.78%
|
18.75
-23.39%
|
24.47
-39.19%
|
40.25
|
| Derivative Product Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Accrued Expenses |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-24.59
+13.65%
|
-28.47
-77.76%
|
-16.02
+13.57%
|
-18.53
|
| Cash Flow From Continuing Operating Activities |
|
-24.59
+13.65%
|
-28.47
-77.76%
|
-16.02
+13.57%
|
-18.53
|
| Net Income From Continuing Operations |
|
-23.49
+30.86%
|
-33.97
-31.73%
|
-25.79
-20.52%
|
-21.40
|
| Depreciation Amortization Depletion |
|
0.23
-14.29%
|
0.27
+5.56%
|
0.25
+7.23%
|
0.23
|
| Depreciation |
|
0.23
-14.29%
|
0.27
+5.56%
|
0.25
+7.23%
|
0.23
|
| Depreciation And Amortization |
|
0.23
-14.29%
|
0.27
+5.56%
|
0.25
+7.23%
|
0.23
|
| Other Non Cash Items |
|
—
|
—
|
0.32
|
—
|
| Stock Based Compensation |
|
2.09
-44.32%
|
3.75
-13.92%
|
4.35
+21.89%
|
3.57
|
| Operating Gains Losses |
|
0.04
-78.97%
|
0.20
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
0.00
-100.00%
|
0.20
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
0.04
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-3.46
-368.40%
|
1.29
-73.42%
|
4.85
+613.89%
|
-0.94
|
| Change In Receivables |
|
-7.24
-415.09%
|
-1.41
-158.76%
|
2.39
+270.06%
|
-1.41
|
| Change In Prepaid Assets |
|
1.17
-28.17%
|
1.63
-11.83%
|
1.85
+242.24%
|
-1.30
|
| Change In Payables And Accrued Expense |
|
3.51
+89.32%
|
1.85
-24.02%
|
2.44
+425.77%
|
-0.75
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
0.34
|
| Change In Payable |
|
—
|
—
|
—
|
-1.09
|
| Change In Account Payable |
|
—
|
—
|
—
|
-1.09
|
| Change In Other Working Capital |
|
-0.70
-10.08%
|
-0.64
+62.36%
|
-1.69
-164.02%
|
2.63
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
-1.73
|
| Change In Other Current Liabilities |
|
-0.20
-28.30%
|
-0.16
-6.00%
|
-0.15
-23.97%
|
-0.12
|
| Investing Cash Flow |
|
0.01
+325.00%
|
-0.00
+97.28%
|
-0.15
+14.04%
|
-0.17
|
| Cash Flow From Continuing Investing Activities |
|
0.01
+325.00%
|
-0.00
+97.28%
|
-0.15
+14.04%
|
-0.17
|
| Net PPE Purchase And Sale |
|
0.01
+325.00%
|
-0.00
+97.28%
|
-0.15
+14.04%
|
-0.17
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.00
+97.28%
|
-0.15
+14.04%
|
-0.17
|
| Sale Of PPE |
|
0.01
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
—
|
-0.00
+97.28%
|
-0.15
+14.04%
|
-0.17
|
| Financing Cash Flow |
|
36.57
+55.19%
|
23.57
+421.23%
|
4.52
-18.48%
|
5.55
|
| Cash Flow From Continuing Financing Activities |
|
36.57
+55.19%
|
23.57
+421.23%
|
4.52
-18.48%
|
5.55
|
| Net Issuance Payments Of Debt |
|
-0.35
+52.23%
|
-0.74
+8.88%
|
-0.81
+41.91%
|
-1.40
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
-0.35
+52.23%
|
-0.74
+8.88%
|
-0.81
+41.91%
|
-1.40
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
-0.35
+52.23%
|
-0.74
+8.88%
|
-0.81
+41.91%
|
-1.40
|
| Net Long Term Debt Issuance |
|
-0.35
+52.23%
|
-0.74
+8.88%
|
-0.81
+41.91%
|
-1.40
|
| Net Common Stock Issuance |
|
37.02
+52.02%
|
24.35
+356.68%
|
5.33
+0.15%
|
5.32
|
| Proceeds From Stock Option Exercised |
|
0.07
-13.41%
|
0.08
|
0.00
-100.00%
|
1.62
|
| Net Other Financing Charges |
|
-0.16
-28.13%
|
-0.13
|
—
|
—
|
| Changes In Cash |
|
11.99
+344.07%
|
-4.91
+57.81%
|
-11.64
+11.51%
|
-13.16
|
| Effect Of Exchange Rate Changes |
|
—
|
0.00
-100.00%
|
0.00
+500.00%
|
-0.00
|
| Beginning Cash Position |
|
25.01
-16.42%
|
29.92
-28.01%
|
41.56
-24.05%
|
54.72
|
| End Cash Position |
|
37.00
+47.95%
|
25.01
-16.42%
|
29.92
-28.01%
|
41.56
|
| Free Cash Flow |
|
-24.59
+13.66%
|
-28.48
-76.17%
|
-16.16
+13.57%
|
-18.70
|
| Common Stock Issuance |
|
37.02
+52.02%
|
24.35
+356.68%
|
5.33
+0.15%
|
5.32
|
| Issuance Of Capital Stock |
|
37.02
+52.02%
|
24.35
+356.68%
|
5.33
+0.15%
|
5.32
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 8-K2026-03-02 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-05 View
- 42026-02-05 View
- 42026-02-05 View
- 8-K2026-01-27 View
- 42025-12-22 View
- 42025-12-22 View
- 42025-12-22 View
- 8-K2025-12-18 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 42025-09-23 View
- 8-K2025-09-15 View
- 8-K2025-08-28 View
- 8-K2025-08-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|